A new generation of healthtech startups is beginning to tackle areas of healthcare long overlooked by digital innovation. One of those is alcohol reduction, a space where millions struggle but modern, accessible treatment options remain limited. UK based startup Nul is aiming to change that reality by combining clinical care, prescription medication, and digital support into a fully remote platform designed for people who want to reduce their alcohol intake without committing to immediate abstinence.
Nul has now raised one million dollars in seed funding to accelerate its growth. The round was led by dmg ventures and BYVP, with participation from a group of angel investors experienced in health, technology, and consumer services.
Addressing a neglected healthcare challenge
Harmful drinking and alcohol use disorder affect millions globally, placing a heavy burden on individuals, families, and healthcare systems. Despite the scale of the problem, innovation in treatment has lagged behind other categories such as weight management and mental health.
Many existing approaches are built around abstinence focused models, which can discourage people who want to reduce consumption gradually rather than stop entirely. Nul is designed to serve this unmet segment by offering evidence based reduction pathways that fit more realistically into everyday life.
A medication supported digital approach
Founded by Matus Maar, Nul delivers a telehealth programme that integrates medical consultations, prescription medication, and structured behavioural support. At the centre of the platform is naltrexone, a medication that reduces alcohol cravings by blocking reward pathways in the brain.
The treatment model follows The Sinclair Method, a clinically supported approach that pairs medication with continued drinking to gradually reduce alcohol dependence over time. Users access the service through a remote subscription that includes virtual doctor consultations, ongoing clinical oversight, and guided digital tools that support habit change and long term progress.
Early traction in the UK market
Nul launched a limited test phase in the UK during summer 2025 to validate demand and refine its offering. In just a few months, the company onboarded more than 120 paying customers and reached an annualised revenue run rate exceeding three hundred thousand pounds.
Growth has been driven primarily by organic demand and word of mouth, suggesting strong interest among people seeking discreet and flexible treatment options outside traditional healthcare settings.
According to founder and CEO Matus Maar, alcohol reduction is one of the last major health categories to benefit from telehealth innovation.
Telehealth and online pharmacy platforms have transformed areas like weight loss and mental health, yet alcohol has been left behind despite the scale of the issue. Nul aims to make evidence based care accessible, discreet, and compatible with real life routines.
Funding to support national rollout and growth
The newly raised seed capital will be used to support Nul’s full commercial launch across the UK. This includes expanding clinical operations, strengthening the product and engineering teams, and scaling customer acquisition efforts.
The company is also preparing for international expansion, with the United States identified as a future priority market due to similar unmet needs and growing acceptance of telehealth based care.
Alongside the seed round, Nul plans to open a crowdfunding campaign on Republic Europe. This move will allow retail investors to participate in the company’s next phase of growth and reflects a broader trend toward community backed health innovation.
Building a new model for alcohol care
By combining medication, clinical oversight, and digital support into a single platform, Nul is positioning itself as a modern alternative to traditional alcohol treatment pathways. Its focus on reduction rather than abstinence reflects changing attitudes toward alcohol use and recovery.
As healthcare continues to move online, Nul’s early traction suggests that alcohol reduction may be ready for the same digital transformation seen in other major health categories.
